Benefits and risks of simvastatin in patients with familial hypercholesterolaemia

Drug Safety

Volumn 26, Issue 11, 2003, Pages 769-786

  Mata, Pedro ^a,c   Alonso, Rodrigo ^a   Badimón, Juan J ^b  

^a Internal Medicine Department   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; AMLODIPINE; APOLIPOPROTEIN B100; CARBAMAZEPINE; CLARITHROMYCIN; COTRIMOXAZOLE; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FELODIPINE; FLUCONAZOLE; FLUOXETINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICONAZOLE; NIFEDIPINE; NORFLOXACIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHENYTOIN; QUINIDINE; SIMVASTATIN; TRIACYLGLYCEROL; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL;

ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CLINICAL FEATURE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIVER DYSFUNCTION; LONG TERM CARE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; TREATMENT PLANNING;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; RISK ASSESSMENT; SIMVASTATIN;

EID: 0042856270     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326110-00003     Document Type: Review

References (103)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 2001: 120, 2863-913
2. Heath K, Gahan M, Whittall R, et al. Low-density lipoprotein receptor gene (LDL-R) world-wide website in familial hypercholesterolemia: update, new features and mutations analysis. Atherosclerosis 2001; 154: 243-6
3. Settel HC, Baker SG, Jenkins T, et al. Prevalence of familial hypercholesterolemia in Johannesburg Jews. Am J Med Genet 1989; 34: 545-7
4. Scientific Steering Committee on behalf of the Simon Broome Register. Risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ 1991; 303: 893-6
5. Mabuchi H, Miyamoto S, Ueda K, et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986; 61: 1-6
6. Miettinen T, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Arteriosclerosis 1988; 8: 163-7
7. Mabuchi H, Koizumi J, Shimizu M, et al. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79: 225-32
8. Mata P, Alonso R, Castillo S, et al. MedPed and the Spanish familial hypercholesterolemia foundation. Atheroscler Suppl 2002; 2: 9-11
9. Alonso R, Castillo S, Civeira F, et al. Heterozygous familial hypercholesterolemia in Spain: description of 819 non related cases. Med Clin (Barc) 2002; 118: 487-92
10. Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature cardiovascular disease. Atherosclerosis 1992; 96: 91-107
11. Miserez AR, Laager R, Chiodetti N, et al. High prevalence of familial defective apolipoprotein B 100 in Switzerland. J Lipid Res 1994; 35: 574-83
12. Kotze MJ, Peeters AV, Langenhoven E, et al. Phenotypic expression and frequency of familial defective apolipoprotein B 100 in Belgian hypercholesterolemics. Atherosclerosis 1994; 111: 217-25
13. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 1771-5
14. Zuliani G, Arca M, Signore A, et al. Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999 Mar; 19: 802-9
15. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292: 1394-8
16. Pullinger C, Eng C, Salen G, et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002; 110: 109-17
17. Celermajer DS, Sorensen KW, Gooch VM, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5
18. Sanpietro T, Tuoni M, Ferdeghini M, et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997; 96: 1381-5
19. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimes. JAMA 1990; 264: 3007-12
20. Thompson GR, Maher VMG, Matthews S, et al. Familial Hypercholesterolemia Regression study: a randomised trial of low density lipoprotein apheresis. Lancet 1995; 345: 811-6
21. Alonso R, Mata P, De Andres R, et al. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 2001; 157: 423-9
22. Tamai O, Matsuoka H, Itabe H, et al. Single LDL-apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82
23. Illingworth DR. How effective is drug therapy in heterozygous familial hypercholesterolemia. Am J Cardiol 1993; 72 Suppl.: 52D-8D
24. World Health Organization. Report of a WHO consultation. WHO/HGN/FH/CONS/98.7. Paris: 1997 Oct
25. Defesche J. Familial hypercholesterolemia. In: Betteridge DJ, editor. Lipid and cardiovascular disease: current issues. London: Martin Dunitz, 2000: 65-76
26. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-95
27. Leiteredorf E, Muratty EN, Eliav O, et al. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995; 76: 84A-8A
28. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
29. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group (WOSCOPS). N Engl J Med 1995; 333: 1301-7
30. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events in patients with average cholesterol levels (CARE). N Engl J Med 1996; 335: 1001-9
31. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with Iovastatin in men and women with average cholesterol levels (AFCAPS/TexCAPS). JAMA 1998; 279: 1615-22
32. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
33. Heart Protective Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
34. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999; 142: 105-12
35. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000; 153: 181-9
36. Knops RE, Kroon AA, Mol MJ, et al. Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolemia. Neth J Med 1995; 46: 171-8
37. Ose L, Kastelein J, Scott R, et al. Efficacy and six-month safety of simvastatin 80 mg/day: results from the worldwide simvastatin expanded dose program (WSDEP). Nutr Metab Cardiovasc Dis 1998; 8: 135-43
38. de Sauvage Nolting P, Burima R, Hutten B, et al. Two-year efficacy and safety of simvastatin 80mg in familial hypercholesterolemia (the examination of probands and relatives in statin studies with familial hypercholesterolemia [ExPRESS FH]). Am J Cardiol 2002; 90: 181-4
39. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25 (9): 649-63
40. Todd PA, Goa KL. Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1990; 40: 583-607
41. Plosker G, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs 1995; 50: 334-63
42. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195-202
43. Cheng H, Rogers JD, Sweany AE, et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992; 9: 1629-33
44. Mol MJ, Erkelens DW, Gevers Leuven JA, et al. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet 1986; 8513: 936-9
45. Mol MJ, Erkelens DW, Gevers Leuven JA, et al. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia. Atherosclerosis 1988; 69: 131-7
46. Hagemenas FC, Pappu AS, Illingworth DR. The effect of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur J Clin Invest 1990; 20: 150-7
47. de Sauvage Nolting P, Burima R, Hutten B, et al. Baseline lipid values partly determine the response to high dose simvastatin in patients with familial hypercholesterolemia: the examination of probands and relatives in statin studies with familial hypercholesterolemia. Atherosclerosis 2002; 164: 347-54
48. Gruer P, Vega JM, Mercuri M, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1998; 84: 811-5
49. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomised in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000; 86: 257-62
50. Raal FJ, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis 1997; 135: 249-56
51. Raal FJ, Pilcher GJ, Veller M, et al. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia: a direct measurement with ultrasound imaging. Am J Cardiol 1999; 84: 1344-6
52. Illingworth DR, Erkelens DN, Keller U, et al. Defined daily doses in relation to hypolipidemic efficacy of lavastatin, pravastatin and simvastatin. Lancet 1995; 343: 1554-5
53. Illingworth DR, Bacon S, Pappu A, et al. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1992; 96: 53-64
54. Wierzbicki AS, Lumb PJ, Semra Y, et al. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hypercholesterolemias Q J Med 1999; 92: 387-94
55. Wierzbicki AS, Lumb PJ, Chik G, et al. Comparison of therapy with simvastatin 80mg and atorvastatin 80mg in patients with familial hypercholesterolemia. Int J Clin Pract 1999; 53: 609-11
56. Smilde TJ, Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81
57. Wierzbicki AS, Lumb PJ, Semra YK, et al. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolemia. Q J Med 1998; 91: 291-4
58. Stein EA, Illingworth DR, Kwiterovich PO, et al. Efficacy and safety of lovastatin in adolescents males with heterozygous familial hypercholesterolemia: a randomised controlled trial. JAMA 1999; 281: 137-44
59. Crowford ML. From the Food and Drug Administration [letter]. JAMA 2002; 287: 1640
60. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1989; 9 Suppl. 1: I145-51
61. Ducobu J, Brasseur D, Chaudron S, et al. Simvastatin use in children [letter]. Lancet 1992 Jun; 339: 1488
62. Stefanutti C, Lucani G, Vivenzio A, et al. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drug Exp Clin Res 1999; 25: 23-8
63. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002; 106: 2231-7
64. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation 1984; 69: 313-24
65. Kroon AA, Aengevaeren W, van der Wert T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826-35
66. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7
67. Simons LA, Sullivan D, Simons J, et al. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolemia Atherosclerosis 1998; 137: 197-203
68. Kroon A, van Asten W, Stalenhoef A. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996; 125: 945-54
69. Smilde TJ, ven den Berkmortel FW, Wollersheim H, et al. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolemia. Eur J Clin Invest 2000; 30: 473-80
70. Sijbrands E, Lombardi MP, Westendorp R, et al. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998; 136 (2): 247-53
71. Heath K, Gudnason V, Humphries SE, et al. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1999; 143: 41-54
72. Chaves FJ, Real JT, Garcia-Garcia AB, et al. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab 2001; 86: 4926-32
73. Vohl MC, Szots F, Lelievre M, et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002; 160: 361-8
74. Ordovas J, Lopez-Miranda J, Perez-Jiménez F, et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113: 157-66
75. Couture P, Brun LD, Szots F, et al. Association of specific LDL receptor-gene mutations with differential plasma lipoprotein response to simvastatin in young French-Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998; 18: 1007-12
76. Castillo S, Reyes G, Tejedor D, et al. A double mutant (N543H+2393del9) allele in the LDL receptor gene in familial hypercholesterolemia: effect on plasma cholesterol levels and cardiovascular disease. Hum Mutat 2002 Dec; 20 (6): 477
77. Carmena R, Roederer G, Mailloux H, et al. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia. Metabolism 1993; 42 (7): 895-901
78. O'Malley J, Illingworth D. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990; 39: 150-4
79. De Knijff P, Stalenhoef AF, Mol MJ, et al. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990; 83: 89-97
80. Ojala J, Helve E, Ehnholm C, et al. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolemia. J Intern Med 1991; 230: 397-405
81. Corti R, Badimon J. Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials. Curr Opin Lipidol 2001; 12: 629-37
82. Takemoto M, Liao J. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9
83. Yokoyama I, Yonekura K, Inoue Y, et al. Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J Nucl Cardiol 2001; 8: 445-51
84. Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000; 20: 2113-9
85. Sanchez-Quesada J, Otal-Entraigas C, Franco M, et al. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1999; 84: 665-9
86. Girona J, La Ville AE, Sola R, et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846-51
87. Ferro D, Basili S, Alessandri C, et al. Simvastatin reduces monocyte-tissue-factor expression in type IIa hypercholesterolaemia. Lancet 1997; 350: 12-22
88. Rezaie-Majd A, Maca T, Bucek R, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocyte from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9
89. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-82
90. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000; 153: 181-9
91. Demuth K. Myara I, Chappey B, et al. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 1996; 16: 773-83
92. Corti R, Fuster V, Fayad ZA, et al. Lipid-lowering by simvastatin induces regression of human atherosclerotic lesions: 2 year follow-up by high-resolution non invasive MRI. Circulation 2002; 106: 2884-7
93. Knopp RM Drug therapy: drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511
94. Boccuzzi SJ, Keegan ME, Hirsch LJ, et al. Long-term experience with simvastatin. Drug Invest 1993; 5: 135-40
95. Lijnen P, Celis H, Fagard R, et al. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens 1994; 12: 59-64
96. Laaksonen R, Jokelainen K, Sahi T, et al. Decrease in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57: 62-6
97. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002; 13: 415-20
98. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40
99. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22 (6): 441-57
100. Pasternak R, Smith S, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-8
101. Goldman L, Goldman PA, Williams LW, et al. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993; 72: 75D-9D
102. Johannesson M, Jonsonn B, Kjekshus J, et al. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6
103. Durrington P. The human and economic costs of undertreatment with statins. Int J Clin Pract 2002; 56: 357-68